CARISMA Announces Multiple Abstracts Accepted for Presentation at 2021 SITC Annual Meeting
PHILADELPHIA, November 1, 2021 — CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today the acceptance of a late breaker abstract for oral presentation of its clinical study data and three pre-clinical study abstracts to be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Anniversary Annual Meeting (November 10 – 14, 2021) in Washington, D.C.
Details of the presentations are as follows:
Late Breaking Oral Presentation:
- A Phase 1 First in Human Study of Adenovirally Transduced Anti-HER2 CAR Macrophages in Subjects with HER2 Overexpressing Solid Tumors: Preliminary Safety, Pharmacokinetics, and TME Reprogramming Data
Poster Presentations:
- Chimeric Antigen Receptor Macrophages (CAR-M) Elicit a Systemic Anti-Tumor Immune Response and Synergize with PD1 Blockade in Immunocompetent Mouse Models of HER2+ Solid Tumors
- SIRP⍺ Deficient CAR-Macrophages Exhibit Enhanced Anti-Tumor Function and Bypass the CD47 Immune Checkpoint
- Development and Characterization of Human Chimeric Antigen Receptor Monocytes (CAR-Mono), a Novel Cell Therapy Platform